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Background
Nitric oxide (NO) functions as a negative regulator of
platelet aggregability, predominantly via activation of sol-
uble guanylate cyclase (sGC); this is also relevant to the
clinical efficacy of NO donors in management of acute
coronary syndromes. However, we have discovered that
acute coronary syndromes are associated with attenuation
of platelet responsiveness to NO donors, independent of
the phenomenon of nitrate tolerance. The phenomenon
of platelet NO resistance has been documented to occur in
association with a number of coronary risk factors (hyper-
tension, diabetes, hyperlipidaemia) and also in non-
ischaemic forms of heart disease.
Epidemiology and prognostic impact
In general, we have documented that severe NO resistance
was seen particularly in patients with unstable angina pec-
toris [1]. However, NO resistance also occurred in the
presence of hyperglycaemia [2], in aortic stenosis (inde-
pendent of the presence of coronary disease), in polycystic
ovarian syndrome [3], and in untreated heart failure [4].
Among patients with unstable angina, NO resistance was
an independent predictor of morbidity and mortality [5].
Mechanistic considerations
Platelet NO resistance reflects a combination of "scaveng-
ing" of NO by reactive oxygen species and (potentially
reversible) impairment of sGC function. Evidence for a
role for superoxide (O2
-) in modulating NO resistance
includes close correlations with whole blood O2
- content
[2], and partial reversal with SOD [6]. We have also docu-
mented an impairment of platelet sGC function in
patients with stable angina pectoris [6]. However, phos-
phodiesterase activity did not appear to modulate NO
resistance.
Therapeutics of NO resistance
We examined the effects of perindopril in patients with
previously untreated congestive heart failure [7]; treat-
ment was associated with partial restoration of SNP
responses. The "metabolic" anti-anginal agent perhexiline
restored platelet responsiveness to NO in patients with
refractory angina, with parallel improvements in sympto-
matic status [8]. In diabetics, treatment of hyperglycaemia
with intravenous insulin infusion also ameliorated plate-
let NO resistance. As an alternative approach, we are cur-
rently testing the hypothesis that NO resistance may be
circumvented either by nitroxyl donors, or "direct" sGC
stimulators (BAY 41-2272) and sGC activators (BAY 58-
2667). Theoretically, these sGC activators offer the advan-
tage of circumventing both NO "scavenging" and inactiva-
tion/oxidation of sGC.
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